

## Profile #1269

Profile #1269 - Medical University of Vienna - Austria

Date: 2007/03/06

Deadline: 2013/12/31

### Contact

<b>Organisation</b>	Medical University of Vienna	<b>Department</b>	Department of Dermatology
<b>Contact person</b>	Epstein, Dr. Michelle		
<b>Email</b>	Michelle.Epstein@meduniwien.ac.at		
<b>Address</b>	Lazarettgasse 19		
<b>Postcode</b>	A1090	<b>City</b>	Vienna
<b>Country</b>	Austria		
<b>Telephone</b>	+43 1 40160 63012	<b>Fax</b>	+43 1 40160 963012
<b>Website</b>	<a href="http://www.meduniwien.ac.at/immundermatologie/?main=fors&amp;sub=52&amp;lang=en">http://www.meduniwien.ac.at/immundermatologie/?main=fors&amp;sub=52&amp;lang=en</a>		

### Organisation

<b>Type:</b>	Research Organisation & Universities
<b>Is a Small and Medium Sized Enterprise (SME)?</b>	NO
<b>Number of Employees</b>	250
<b>Description of research activity:</b>	The experimental allergy group is part of the Department of Dermatology at the Medical University of Vienna. We are an academic institution but have continuing collaborations with other University laboratories and Pharmaceutical Companies.

<b>Former participation in an FP European project?</b> YES	
<b>Project title / Acronym:</b>	---
<b>Activities performed::</b>	Coordinator for FP7 small collaborative project (starting 07/2008)and Marie Curie IIF (starting 06/2008)

### Expertise/commitment offered

<b>Keywords specifying the expertise:</b>	immunology, allergic disease, allergic asthma, lung inflammation, animal models, Innovative Medicines Initiative (IMI)
-------------------------------------------	------------------------------------------------------------------------------------------------------------------------

<b>Description of the expertise:</b>	Our laboratory group is focused on dissecting the mechanisms underlying the initiation and perpetuation of Th2 lymphocyte-mediated allergic asthma. We use animals models for studying pathophysiology, searching for drug targets and testing novel compounds for their effect on acute and exacerbating allergic asthma.
<b>Commitment offered</b>	Research

## Expectations

<b>Term commitment:</b>	Long ( > 3 years)
<b>Expected results for your organisation:</b>	<p>We seek to work together with industry and academia using our acute and chronic animal models. We expect to further characterise the early processes in the pathogenesis of allergic asthma, a chronic inflammatory disease that is dependent upon memory Th2 cells. We have been pursuing the induction of these pathogenic Th2 cells in allergic asthma and expect to continue with this aim with the ultimate objective of discovering new strategies to abrogate memory Th2 responses and by doing so, inhibit allergic asthma.</p> <p>Our work with animal models is aimed at the further understanding of the pathophysiology of relapsing and remitting allergic asthma, pathogenic allergen-specific memory Th2 lymphocytes, and specific treatments for this disease. In addition, we are keen to work with other partners to test the safety of plant vaccines, GMOs, nanoparticles, etc.</p> <p>Additionally, we would be interested to join a consortium applying for the Topic <b>"Understanding Severe Asthma" in the first Call of the Innovative Medicines Initiatives (IMI)</b>. More specifically, we offer to contribute to the call by assisting in the understanding of the aetiology and pathogenetic mechanism of asthma exacerbations in animal models, thus enabling the identification of new targets and therapeutic approaches. Therefore, we would contribute to the following listed Deliverable in the call: <b>Understanding of aetiology and pathogenesis of asthma exacerbations as mechanism to identify new targets and therapeutic approaches</b> especially with regard to delaying time to exacerbation and reducing severity of exacerbation, which ultimately will deliver significant pharmaco-economic benefits.</p>